Side by side: size, value over time, results, valuation, margins, growth, debt and shareholder returns, and any of thirty figures charted over the years (up to 6).
Open these as a peer group: up to 12 companies with suggested peers, each company's rank in the group and percentile in its sector and country, saved for you or your team.
US$ billions, as reported in each year's annual results.
Revenue of the fiscal year. US dollars at each year's exchange rate.
| Measure | Indivior PLC✕ INDV · #3,650 in the world |
|---|---|
| Profile | |
| Country | 🇬🇧 UK |
| Sector | Healthcare |
| Industry | Pharmaceutical |
| Founded | 1994 |
| Size | |
| Market cap | $4.9 B |
| Revenue | $1.2 B |
The largest companies, each against its nearest peers in value from the same industry.
| Fiscal year | Indivior PLC |
|---|---|
| 2025 | $1.2 BSEC |
| 2024 | $1.2 BSEC |
| 2023 | $1.1 BSEC |
| 2022 | $901 MSEC |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports; Ed. = the company's report (editors); WD = Wikidata, citing the annual report; Cap = value.today market caps. Hover a figure for its period.
| $210 M |
| Valuation | |
|---|---|
| P/E ratio | 10.8× |
| Price to sales | 3.5× |
| Free cash flow yield | -1.9% |
| Profitability | |
|---|---|
| Gross margin | 80.2% |
| Operating margin | 21.1% |
| Net margin | 16.9% |
| Growth | |
|---|---|
| Revenue growth | 4.3% |
| Revenue growth, 3 years a year | 11.2% |
| Financial strength | |
|---|---|
| Net debt to EBITDA | 0.3× |
| Interest cover | 6.9× |
| Cash | |
|---|---|
| Free cash flow margin | -7.5% |
| Shareholder returns | |
|---|---|
| Shareholder yield | 0.2% |
| Strength scores | |
|---|---|
| Piotroski F-score | 4 of 9 |
| Altman Z-score zone | safe |
|---|
| Data as of | Market cap Aug 2026; ratios FY2025 |
|---|
Market caps from exchange data or SEC filings on the date shown (* last known value, no current one); revenue and net income from the latest annual results; ratios worked out from each company's own statements for the fiscal year shown. ▲ marks the best of these companies where higher or lower is better; size and valuation multiples are marked for no one. Definitions: methodology.